Published in Circulation on November 05, 2002
Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ (2006) 5.03
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract (2008) 1.49
Night-time blood pressure patterns and target organ damage: a review. Can J Cardiol (2007) 1.12
Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall. BMC Health Serv Res (2006) 1.01
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens (2015) 0.90
Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag (2008) 0.90
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens (2015) 0.88
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Vasc Health Risk Manag (2009) 0.85
Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension. J Gen Intern Med (2016) 0.85
Carotid intima-media thickness studies: study design and data analysis. J Stroke (2013) 0.84
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. Vasc Health Risk Manag (2009) 0.83
The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. PLoS One (2013) 0.83
Cardiovascular disease risk in the offspring of diabetic women: the impact of the intrauterine environment. Exp Diabetes Res (2012) 0.81
Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs. Eur J Clin Pharmacol (2009) 0.81
Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a calcium channel blocker (CCB) following ineffective CCB monotherapy. J Thorac Dis (2015) 0.81
Reproducibility of 3-dimensional ultrasound readings of volume of carotid atherosclerotic plaque. Cardiovasc Ultrasound (2008) 0.80
Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation. Int J Exp Pathol (2004) 0.80
2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clin Hypertens (2015) 0.79
Residual Cardiovascular Risk in Individuals on Blood Pressure-Lowering Treatment. J Am Heart Assoc (2015) 0.79
Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Eur J Clin Pharmacol (2007) 0.79
IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol (2012) 0.79
Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. Jpn J Ophthalmol (2010) 0.78
Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med (2014) 0.78
Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag (2007) 0.78
Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice. PLoS One (2013) 0.78
Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials. Integr Blood Press Control (2009) 0.78
Individualization of antihypertensive drug treatment. Diabetes Care (2013) 0.77
Enzymatically Modified Low-Density Lipoprotein Promotes Foam Cell Formation in Smooth Muscle Cells via Macropinocytosis and Enhances Receptor-Mediated Uptake of Oxidized Low-Density Lipoprotein. Arterioscler Thromb Vasc Biol (2016) 0.77
Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine. Am J Physiol Heart Circ Physiol (2004) 0.77
Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure. Vascul Pharmacol (2010) 0.77
Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development. PLoS One (2014) 0.77
Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells. BMC Res Notes (2012) 0.77
Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial. Hypertension (2011) 0.77
Is amlodipine more cardioprotective than other antihypertensive drug classes? Korean J Intern Med (2014) 0.77
Results of a 14-Week, Multicenter, Prospective, Randomized, Open-Label, Noninferiority Clinical Trial Comparing the Antihypertensive Effect and Edema Incidence of Lacidipine and Amlodipine in Older Korean Patients with Mild-to-Moderate Hypertension. Curr Ther Res Clin Exp (2013) 0.76
Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials. Chin Med J (Engl) (2016) 0.76
Secular Trends in Prescription Patterns of Single-Pill Combinations of an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Plus a Thiazide Diuretic for Hypertensive Patients in Taiwan. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.75
Effect of Lacidipine on Blood Pressure and Endothelial Function in Mild-to-Moderate Essential Hypertension Patients With Diabetes in Korea. Korean Circ J (2010) 0.75
Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications. J Diabetes Investig (2012) 0.75
Global cardiovascular risk assessment in the management of primary hypertension: the role of the kidney. Int J Hypertens (2013) 0.75
Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia. J Zhejiang Univ Sci B (2015) 0.75
Carotid artery intima-media thickness and hypertensive heart disease: a short review. Clin Hypertens (2017) 0.75
Differential effects of the changes of LDL cholesterol and systolic blood pressure on the risk of carotid artery atherosclerosis. BMC Cardiovasc Disord (2012) 0.75
Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial. Hypertens Res (2016) 0.75
The calcium channel blocker lacidipine slows the progression of carotid atherosclerosis. Rev Cardiovasc Med (2003) 0.75
Discovery and Development of Calcium Channel Blockers. Front Pharmacol (2017) 0.75
The role of calcium antagonists in patients with chronic renal failure. Pediatr Nephrol (2005) 0.75
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A (2003) 15.81
Point: cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol (1985) (2006) 11.52
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91
Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA (2003) 4.88
Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation (2005) 4.69
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens (2011) 3.50
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2003) 3.43
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
13C-angiography. Acad Radiol (2002) 3.24
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens (2005) 3.15
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension (2007) 2.94
Assumed oxygen consumption frequently results in large errors in the determination of cardiac output. J Thorac Cardiovasc Surg (2005) 2.87
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 2.78
Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens (2003) 2.72
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation (2002) 2.44
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension (2007) 2.43
Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol (2011) 2.40
Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension (2011) 2.32
Seasonal blood pressure changes: an independent relationship with temperature and daylight hours. Hypertension (2013) 2.30
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24
ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens (2012) 2.24
Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens (2002) 2.15
Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension (2002) 2.15
Effect of area-based deprivation on the severity, subtype, and outcome of ischemic stroke. Stroke (2003) 2.13
Can ambulatory blood-pressure monitoring provide reliable indices of arterial stiffness? Am J Hypertens (2007) 2.13
Enhanced baroreceptor control of the cardiovascular system by polyunsaturated Fatty acids in heart failure patients. J Am Coll Cardiol (2006) 2.09
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
Weather-related changes in 24-hour blood pressure profile: effects of age and implications for hypertension management. Hypertension (2005) 2.05
The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens (2002) 2.03
Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation (2002) 1.95
Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke (2002) 1.93
Failure of monolateral renal nerve ablation to exert sympathoinhibitory and blood pressure lowering effects in a patient with resistant hypertension: a case report. Int J Cardiol (2013) 1.91
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension (2004) 1.90
Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (The Bogalusa Heart Study). Am J Cardiol (2002) 1.88
Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. Nature (2004) 1.86
Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens (2006) 1.86
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med (2002) 1.77
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens (2002) 1.74
Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension (2011) 1.73
Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension (2007) 1.71
Increased arterial stiffness in normoglycemic normotensive offspring of type 2 diabetic parents. Hypertension (2008) 1.71
Blood pressure variability and silent cerebral damage in essential hypertension. Am J Hypertens (2004) 1.69
Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology (2006) 1.68
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Effect of supplementation with antioxidants upon long-term risk of hypertension in the SU.VI.MAX study: association with plasma antioxidant levels. J Hypertens (2005) 1.67
Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J (2013) 1.66
Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension (2008) 1.65
Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord (2005) 1.63
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int (2012) 1.63
Methods and devices for measuring arterial compliance in humans. Am J Hypertens (2002) 1.61
The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment. Structure (2006) 1.60
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie (2011) 1.57
Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension (2009) 1.56
Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens (2008) 1.55
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation (2006) 1.54
Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. Hypertension (2012) 1.54
Effects of heart rate changes on arterial distensibility in humans. Hypertension (2003) 1.52
Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med (2004) 1.51
Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke (2005) 1.51
Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol (2005) 1.50
Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens (2009) 1.50
Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology (2002) 1.49
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Influence of sex on the relation between heart rate and aortic stiffness. J Hypertens (2003) 1.48
Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens (2005) 1.47
Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens (2005) 1.47
Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand? J Clin Hypertens (Greenwich) (2013) 1.44
When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens (2009) 1.43
Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hypertens (2002) 1.43
Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens (2007) 1.42
Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension (2003) 1.42
Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis (2013) 1.42
Do other cardiovascular risk factors influence the impact of age on the association between blood pressure and mortality? The MORGAM Project. J Hypertens (2014) 1.41
Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens (2002) 1.41
Structure of the acid-sensing ion channel 1 in complex with the gating modifier Psalmotoxin 1. Nat Commun (2012) 1.41
The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. J Hypertens (2004) 1.40